Skip to main content

Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Key Executives

NameTitle
Leonard S. SchleiferCEO/Co-Chairman of the Board/Co-Founder/Co-President/Director
Neil StahlExecutive VP, Divisional
George D. YancopoulosChief Scientific Officer/Co-Chairman of the Board/Co-President/Director
Joseph J. LarosaExecutive VP/General Counsel/Secretary
Daniel P. Van PlewExecutive VP/General Manager, Divisional
Marion McCourtExecutive VP, Divisional
Christopher R. FenimoreChief Accounting Officer/Controller/Senior VP
Andrew J MurphyExecutive VP, Divisional
Jason PitofskyController/Vice President